Abakkus buys ₹100 crore of Jubilant Pharmova at ₹915 as Quant sells: June-quarter profit fell 45% to ₹56 crore and the stock trades at 39 times earnings
On 12 October, Abakkus Four2Eight Opportunities Fund bought 11 lakh shares of Jubilant Pharmova at ₹915, about ₹100.65 crore. The seller was Quant Mutual Fund, which sold a total of 20.81 lakh shares (about ₹190 crore) that day. The buyer sits in Sunil Singhania's Abakkus group. The trade is a small slice of the company, about 0.7% of its shares. The more important facts are in the business: June-quarter profit fell 45% to ₹56 crore, and the stock trades at about 39 times earnings.
Jubilant Pharmova Limited (NSE: JUBLPHARMA) - Share price: ₹951 (12 October close) - Market cap: ₹15,148 crore - P/E: about 39x as shown by screener.in, which does not say which earnings period it uses. By my arithmetic, market cap is 38x FY26 profit (₹398 crore) and 43x the last twelve months' profit (₹351 crore) - Book value: ₹445 per share, so price to book is about 2.1x - Peer P/E: Syngene International 50.7x. Piramal Pharma has had a loss over the last twelve months, so it has no P/E - 52-week range: ₹784 to ₹1,185. The price is 20% below the high and 21% above the low
What happened on 12 October
Detail ------ Buyer Abakkus Four2Eight Opportunities Fund (news reports name Abakkus Asset Managers, led by Sunil Singhania) Seller Quant Mutual Fund Quantity and price 11,00,000 shares at ₹915, about ₹100.65 crore Quant's total sale 20.81 lakh shares, about ₹190 crore, so about half went to other buyers Share of company Abakkus about 0.7%, Quant's total sale about 1.3% (of about 15.9 crore shares) Stock that day Up 2.0% to ₹950.90 on NSE
Source: exchange bulk-deal data (NSE) and news reports. Neither stake is near 5%, the level at which a separate substantial-shareholding disclosure applies.
The same evening the board approved a private placement of non-convertible debentures (NCDs, bonds) of up to ₹800 crore. The company is also seeking shareholder approval for a borrowing limit of ₹2,500 crore.
Abakkus has been buying through its other funds too. These are estimates based on monthly portfolio disclosures, not actual trade prices:
- Abakkus Small Cap Fund added about 7.8 lakh shares between April and August 2026 - Abakkus Flexi Cap Fund added about 5.5 lakh shares in August 2026
Business and history
Jubilant Pharmova was incorporated in 1978 as Vam Organic Chemicals, at Gajraula in Uttar Pradesh. It became Jubilant Organosys (2001), Jubilant Life Sciences (2009) and Jubilant Pharmova (February 2021). It has about 5,500 employees. The promoters are the Bhartia family.
It earns money from several businesses. The figures are for the June 2026 quarter. The businesses shown add up to ₹2,214 crore. The rest of the ₹2,229 crore total is other revenue and adjustments.
- Radiopharmacy (₹700 crore). The second-largest network of radiopharmacies in the US by network size, per the company, with 45 sites. It makes and delivers doses for scans. Profit margin is thin, ₹12 crore on ₹700 crore. - CDMO sterile injectables (₹496 crore). A CDMO makes medicines for other drug companies. Here it fills injectable medicines at its plants in Spokane (US) and Montreal (Canada). - Radiopharma (₹322 crore). It makes imaging products, including the Ruby-Fill heart-scan generator. EBITDA was ₹110 crore. - Allergy immunotherapy (₹214 crore). No. 2 in the US. It is the only US supplier of venom. - Drug discovery (₹174 crore), generics (₹173 crore) and APIs (₹135 crore, the active ingredient in medicines).
Latest results: June 2026 quarter
₹ crore June 2026 June 2025 Change ------------ Revenue 2,229 1,901 +17% EBITDA (EBITDA) 268 302 -11% EBITDA margin 11.9% 15.8% -385 basis points Net profit (PAT) 56 103 -45%
Source: company results release, 10 August 2026.
Why profit fell:
- The Montreal plant was not making SPECT products, which are used in medical scans. They normally earn high margins, so their absence hurt profit - Almost no third-party revenue at Montreal, and extra remediation costs there - Higher depreciation after Line 3 started in Spokane
The shares fell about 6% after the results, according to one report.
Five-year trend
₹ crore FY22 FY23 FY24 FY25 FY26 Last 12 months --------------------- Sales 6,130 6,282 6,703 7,234 8,280 8,608 Operating profit 1,150 779 901 1,173 1,260 1,218 Operating margin 19% 12% 13% 16% 15% 14% Net profit 413 -65 73 836 398 351 EPS (₹) 25.98 -3.83 4.84 52.69 25.02 22.11
Source: screener.in, consolidated. The company's own FY26 EBITDA was ₹1,326 crore (15.9% margin), slightly different from the operating profit above. FY25 profit includes about ₹410 crore of other income in the June 2024 quarter. The data I used does not say what it was, so do not treat FY25 as normal. The company also reports a "normalised" profit that removes one-off items: ₹442 crore for FY26, against ₹398 crore reported.
Sales grew 35% in four years. Profit has not followed, and return on equity was 6.5% and return on capital employed about 9% in FY26.
Cash, debt and spending
- Cash from operations was ₹1,227 crore in FY26, three times profit. Depreciation (₹440 crore), a non-cash cost, is part of the gap. Interest, tax and working capital also matter. - Free cash flow was about -₹120 crore, because of heavy spending on new lines. - In FY26, customers took about 47 days to pay (debtor days). Stock sat in inventory for about 170 days, and the company took about 170 days to pay its suppliers. The cash conversion cycle, the time cash is tied up in running the business, was 47 days, down from 124 days two years ago. - At March 2026 the company reported net debt of ₹1,952 crore, about 1.3 times EBITDA. Screener.in shows total borrowings of ₹3,615 crore, which includes lease liabilities. Net debt and total borrowings are different measures. - Interest cost is about ₹217 crore over the last twelve months, so profit before interest and tax covers it about 3.5 times (my arithmetic).
Projects under construction rose from ₹1,090 crore to ₹4,040 crore in four years. That is the money behind Spokane Line 3 and Line 4, the Montreal Line 5 and the new PET sites.
Valuation against peers
Jubilant Pharmova Syngene International Piramal Pharma ------------ Market cap ₹15,148 crore ₹15,014 crore ₹26,182 crore Last 12 months' sales ₹8,608 crore ₹3,600 crore ₹9,205 crore Last 12 months' profit ₹351 crore ₹221 crore Loss of ₹314 crore P/E (screener.in) 39x 50.7x None (loss) Market cap divided by last 12 months' profit (my arithmetic) 43x 68x None (loss) Return on capital employed 9.0% 10.0% 2.5%
Source: screener.in, 13 October 2026. Both peers are contract manufacturers and research providers. Neither has Jubilant's radiopharmacy business, so no peer is an exact match. On the company's own EBITDA, enterprise value (market cap plus net debt, about ₹17,100 crore) is about 12.9 times FY26 EBITDA of ₹1,326 crore.
Did management deliver what it promised?
Given (date) Promise Actual Verdict ------------ Feb 2025 (Vision 2030) Double FY24 revenue by FY30 (about ₹13,400 crore), EBITDA margin 23-25%, net debt to zero, return on capital in the high teens FY26 revenue ₹8,280 crore (up 24% on FY24), margin 15.9%, net debt ₹1,952 crore, ROCE about 9% Behind. Revenue needs about 13% a year from here Oct 2025 (Q2 FY26 call) EBITDA margin to strengthen over the full year FY26 margin 15.9%, down 99 basis points Missed Feb 2026 (Q3 FY26 call) SPECT shortage to hit Q4 FY26 and Q1 FY27, normal from Q2 FY27 Q4 FY26 margin 15.7% (down 272 basis points), Q1 FY27 margin 11.9%. SPECT batches are due for release in Q2 FY27 As warned so far May 2026 (Q4 FY26 call) Radiopharma to grow at a low double-digit rate with a 38-40% margin Q1 FY27 growth 19%, margin about 34% (₹110 crore on ₹322 crore) Growth met. Margin lower, as flagged for the first half May 2026 Line 3 commercial production in late FY27 subject to FDA approval USFDA approved Line 3 on 23 August 2026 On track May 2026 Montreal loss in FY27 similar to FY26 (about ₹200 crore including one-offs) Extra remediation costs in Q1. The FDA also issued a warning letter on 28 May 2026 Too early, but a new risk
Margins and capacity
- Margin path. Operating margin by quarter (screener.in): 15%, 17%, 14%, 15% and 11% for June 2025 to June 2026. The CFO said the second half of FY27 should be at 17-18%. - Spokane (US). Revenue rose 43% to ₹494 crore in the June quarter and EBITDA 49% to ₹117 crore, a 24% margin. Line 3 started in Q2 FY26. Line 4 is installed. - Montreal (Canada). The site lost about ₹200 crore in FY26 including one-offs, per management. The FDA inspection in October-November 2025 led to a warning letter dated 28 May 2026. It cites failure to prevent contamination, weak investigation of batch failures and an ineffective quality system. The company says it has responded to the FDA and continues to run the site under tighter controls. The FDA has not said the issues are resolved, so this remains a live regulatory risk. - New PET radiopharmacies. Six new sites, an investment of more than US$60 million, bring the network to nine sites in FY28.
Management's outlook (its own forward-looking statements)
These come from the May 2026 earnings call and the August 2026 results release. They are plans, not promises.
Group - Growth momentum to strengthen in FY27. Margin is a story of two halves: lower in H1, 17-18% in H2 FY27 - No new capex over the next 12-18 months beyond Line 3, Line 4, Line 5 and the PET sites - Net debt to fall from FY28 and reach zero by FY30 - Tax rate about 33%, to fall gradually as profit rises
Radiopharma and radiopharmacy - SPECT commercial batches released in Q2 FY27 and the full portfolio available by H2 FY27. The H1 FY27 revenue loss from SPECT is about US$14 million - Low double-digit revenue growth in FY27 with a 38-40% margin - Ruby-Fill install base up 26% on an annual basis. The market grows about 10% a year - MIBG (a drug for rare tumours): NDA filing in H2 FY27, accelerated review of about six months, and the company plans to launch it itself - New PET and SPECT products from FY28 to FY29 - The first three of six new PET sites to be commercial next year. Each takes three to four years to reach peak
CDMO sterile injectables - Line 3: more than 10 products being prepared for manufacturing (technology transfer), about 80% of them complex biologics, which are medicines made from living cells. One is among the world's largest oncology products. Commercial batches in late FY27. Peak revenue of US$80-90 million for Line 3, reached 1.5 to 2 years earlier than first planned - Line 4: technology-transfer revenue from Q4 FY27 - Line 5 (Montreal): revenue from FY29. Losses at Montreal to fall in FY28, with no break-even date given - Strong enquiries from US innovators seeking US-based manufacturing because of tariffs
Other businesses - Allergy: the US market grows 3-5%. The company aims to gain share and grow in Europe, where its share is low. About 8-10% of revenue is outside the US - Drug discovery: more than ₹650 crore of FY26 revenue. Large-pharma competition to rise, biotech demand to improve - API: margin about 15%, to rise with custom manufacturing from FY27. Raw material costs, hit by the Middle East conflict, may cut margins in coming quarters - Generics: margin close to 15%, with several launches planned for FY27 - Proprietary drugs JBI-802 and JBI-778 are in clinical trials
Industry size
The radiopharmaceutical market is estimated at about US$10.4 billion in 2025, growing at about 15% a year to about US$21 billion in 2030 (MarketsandMarkets). Other firms give anywhere from US$11 billion to US$29 billion for 2030, because they count different things. I did not find a reliable size for the sterile-injectable CDMO market. The US allergy immunotherapy market grows 3-5% a year, per management.
Who owns the stock
- Promoters hold 47.67%, down from 50.67% in the June 2025 quarter. News reports said promoter companies sold shares in a June 2025 block deal. In August 2025, the Shyam Sunder Bhartia Family Trust pledged about 1.3% of the shares for a group company's loan. - Domestic institutions went from 3.8% (March 2024) to 12.4%. Foreign funds went from 19.1% to 15.9%. - Funds that bought (estimates based on monthly portfolio disclosures): Bandhan Small Cap Fund added about 37.6 lakh shares in June 2026 alone, around ₹363 crore at the month-end price. Abakkus funds are building as shown above. - Quant Mutual Fund was the seller on 12 October. An older table shows a larger Quant holding, but it is undated, so I have not used it.
Management and governance
- Shyam S. Bhartia, Chairman and co-founder of the group. Commerce graduate (St. Xavier's College, Calcutta University) and cost accountant. - Hari S. Bhartia, Co-Chairman and non-executive director. Former President of the Confederation of Indian Industry (2010-11). - Priyavrat Bhartia, Managing Director, son of Shyam Bhartia. Economics degree from Dartmouth and an MBA from Stanford. About 26 years of experience. On the board since 2017. Reappointed MD for three years from 1 June 2026, subject to shareholder approval. - Arjun Shanker Bhartia, Joint Managing Director, son of Hari Bhartia. Brown University graduate (2008), previously at Bain & Company. - The CFO changed on 23 May 2026 (Ashish Mukkirwar replaced Arun Kumar Sharma). A whole-time director, Arvind Chokhany, left the board on 30 September 2025. - On 13 October the company disclosed the resignation of a director or senior manager. The exchange filings I read did not name the person or give a reason. NSE also asked the company about a volume spike that day. - A GST show-cause notice was disclosed on 1 September 2026. The amount is not stated.
Risks and red flags
- FDA warning letter for the Montreal plant, a plant where it is also building a new line - Debt is high and free cash flow is negative while it builds capacity - Profit is thin and swings. Return on equity is 6.5%. A tax rate near 35% takes a large share of profit - Margins rely on SPECT supply returning and on Lines 3 and 4 starting commercial sales on time - API prices and costs. Industry-wide price pressure and higher raw material costs - New debt. The rate, term and use of the up-to ₹800 crore NCD placement are not disclosed in the filings I read - Unnamed resignation and an NSE volume query on 13 October
What does the trade tell us?
Abakkus paid ₹915, below the ₹951 close that same day, for a position of about ₹100 crore. That is a small position in a ₹15,000 crore company, so it signals interest, not a takeover of the story. It does not remove the risks above. The stock prices in the recovery that management expects from the second half of FY27.
The key point A fund buying about 0.7% is a data point, not a reason. The reason to own or avoid Jubilant is whether the second-half margin recovery and the new injectable lines arrive on schedule.
Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.
Sources
- https://www.jubilantpharmova.com/Uploads/files/547pressfileJPMQ1FY27ResultsPressRelease(1).pdf - Jubilant Pharmova earnings webinar transcript for Q4 and FY2026, 22 May 2026 (NSE filing of 27 May 2026) - https://www.whalesbook.com/news/English/stock-investment-ideas/Abakkus-Increases-Jubilant-Pharmova-Stake-Qualcomm-Exits-Shadowfax/6accf6d279a16deaeaeec3c6 - https://www.inkl.com/news/jubilant-pharmova-block-deal-quant-mutual-fund-offloads-rs-190-crore-stake-amid-rs-800-crore-fundraising-plan-abakkus-buys-11-lakh-shares - https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jubilant-hollisterstier-general-partnership-723537-05282026 - https://www.biospace.com/business/jubilant-draws-fda-rebuke-for-delayed-mold-investigation-and-quality-unit-lapses - https://www.outlookbusiness.com/news/jubilant-group-promoters-sell-shares-worth-rs-1801-crore - https://www.marketsandmarkets.com/Market-Reports/radiopharmaceuticals-market-417.html - https://www.multibagg.ai/market-pulse/articles/jubilant-pharmova-vision-2030-92022 - https://www.jubilantpharmova.com/about-us/management/board-of-directors/arjun-shanker-bhartia - https://boardstewardship.com/priyavrat-bhartia-reappointed-as-md-of-jubilant-pharmova-arjun-shanker-bhartia-reappointed-as-joint-md/